Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib.
Jeng-Sen TsengJeng-Sen TsengZhe-Rong ZhengCheng-Hsiang ChuKun-Chieh ChenMong-Wei LinYen-Hsiang HuangKuo-Hsuan HsuTsung-Ying YangSung-Liang YuJin-Shing ChenChao-Chi HoGee-Chen ChangPublished in: Therapeutic advances in medical oncology (2024)
-mutant LAD, those who underwent PTCT had a significantly better survival outcome than those who did not. The survival benefits were consistent across different subgroups.